Facebook Tracking Image

National Comprehensive Cancer Network

Interactive CME


Educational Events & Programs

NCCN Policy Summit:
Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care

 

NCCN POLICY SUMMIT DATE > Thursday, September 12, 2019 > Register Now!

NCCN POLICY SUMMIT LOCATION > The National Press Club • Washington, DC

 

OVERVIEW

Register now! The NCCN will host a Policy Summit: Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care on September 12, 2019 in Washington, DC.

The summit will present diverse perspectives related to defining, measuring, and paying for quality as cancer care is inundated with innovative, personalized, and high-cost interventions. Experts in the field will discuss the role of outcomes-based oncology quality measures in policy decision-making, including how the patient experience is considered and applied in clinical decision-making. The summit will also evaluate how clinical utility and personalized medicine outcomes shape the health care system.  These discussions will culminate with how the various measures, policies, and regulations ultimately impact patient care.

Please check back often for additional updates regarding the summit. If you have any meeting content or agenda questions, please contact Lindsey Bandini, MPH, Quality of Oncology Care Fellow, U.S. and Global Development. For any media questions, please contact Rachel Darwin, Public Relations Manager.


AGENDA*

Please check back often for additional updates.    


SUPPORTERS

Supported by Adaptive Biotechnologies; AmerisourceBergen; Apobiologix; Astellas; AstraZeneca through its NCCN Corporate Council Membership; Bristol-Myers Squibb; Celgene Corporation; Eisai Inc.; EMD Serono; Ferring Pharmaceuticals; Foundation Medicine; HELSINN; Heron; Incyte Corporation; Kite, a Gilead Company; an independent educational grant from Merck & Co., Inc.; Novartis; Regeneron Pharmaceuticals Inc; Tesaro; Verastem Oncology. Sponsored by Boehringer Ingelheim Pharmaceuticals Inc; Dendreon Pharmaceuticals LLC; Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson; This activity was made possible by Pharmacyclics, an AbbVie Company; This activity is supported by a contribution from Lilly.

As of June 21, 2019.


Access the Library of White Papers!

NCCN offers a broad library of white papers from previous summits that may be pertinent to your organization.

View Supporter Opportunities.

NCCN offers organizations various supporter opportunities.